高级检索

黏附分子和血管内皮生长因子在卵巢上皮性肿瘤中的表达及临床意义

苏悦, 韩素萍

苏悦, 韩素萍. 黏附分子和血管内皮生长因子在卵巢上皮性肿瘤中的表达及临床意义[J]. 实用临床医药杂志, 2010, (11): 8-11. DOI: 10.3969/j.issn.1672-2353.2010.11.003
引用本文: 苏悦, 韩素萍. 黏附分子和血管内皮生长因子在卵巢上皮性肿瘤中的表达及临床意义[J]. 实用临床医药杂志, 2010, (11): 8-11. DOI: 10.3969/j.issn.1672-2353.2010.11.003
shu
SU Yue, HAN Su-ping. Expression and clinical significance of MUC4 and VEGF in ovarian epithelial tumor[J]. Journal of Clinical Medicine in Practice, 2010, (11): 8-11. DOI: 10.3969/j.issn.1672-2353.2010.11.003
Citation: SU Yue, HAN Su-ping. Expression and clinical significance of MUC4 and VEGF in ovarian epithelial tumor[J]. Journal of Clinical Medicine in Practice, 2010, (11): 8-11. DOI: 10.3969/j.issn.1672-2353.2010.11.003
shu

黏附分子和血管内皮生长因子在卵巢上皮性肿瘤中的表达及临床意义

  • 南京医科大学第一临床医学院,妇产科,江苏,南京,210009

基金项目: 江苏省科技厅社会发展项目
详细信息

  • 中图分类号: R737.31

Expression and clinical significance of MUC4 and VEGF in ovarian epithelial tumor

摘要

    摘要
  • 摘要: 目的 研究黏附分子(MUC4)和血管内皮生长因子(VEGF)在卵巢上皮性肿瘤中的表达及临床意义.方法 采用免疫组化技术检测20例卵巢良性肿瘤、10例卵巢交界性肿瘤、60例卵巢上皮性卵巢癌组织进行MUC4和VEGF的表达.结果 MUC4和VEGF在卵巢良性肿瘤、交界性瘤、上皮性卵巢癌表达差异有显著性(P<0.05); MUC4和VEGF在卵巢癌中低分化组织中表达率与高分化组织中相比,差异有显著性(P<0.01); 在Ⅰ、Ⅱ期(早期)和Ⅲ、Ⅳ期(晚期)卵巢癌组织中, VEGF的表达差异有显著性(P<0.01), 两组中MUC4的表达差异无显著性;在CA125正常组和CA125升高组中, VEGF的表达差异有显著性(P<0.01), 两组中MUC4的表达差异无显著性;在早期上皮性卵巢癌中, MUC4表达高于VEGF, 差异有显著性(P<0.01).结论 MUC4与卵巢肿瘤的良恶性、病理分级有关,与临床分期、CA125值无关,VEGF与卵巢肿瘤的良恶性、临床分期、CA125值、病理分级有关.MUC4是上皮性卵巢癌早期诊断的候选指标, VEGF与预后有关, 2者联合检测可提高对上皮性卵巢癌诊断的敏感度,能更好的评估病情及预后.
    • HTML全文
    • 参考文献(14)
  • Menon U, Jacobs I. Screening for ovarian cancer [J]. Best Practice and Research:Clinical Obstetrics & Gynaecology, 2002(4):469.
    van Nagell JR Jr, DePriest PD, Reedy MB. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer [J]. Gynecologic Oncology, 2000(3):350.doi: 10.1006/gyno.2000.5816.
    Auersperg N, Wong AS, Choi KC. Ovarian surface epithelium:biology, endocrinology, and pathology [J]. Endocrine Reviews, 2001(2):255.doi: 10.1210/er.22.2.255.
    Karayiannakis AJ, Syrigos KN, Zbar A. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery [J]. Surgery, 2002(5):548.doi: 10.1067/msy.2002.123011.
    Garzetti GG, Ciavattini A, Lu carini G. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas:relationship with M1B1 immunostaining [J]. Gynecologic Oncology, 1999.396.doi: 10.1006/gyno.1999.5377.
    Hollingsworth MA, Swanson BJ. Mucins in cancer:protection and control of the cell surface [J]. Nature Reviews Cancer, 2004(1):45.
    Singh AP, Chaturvedi P, Batra SK. Emerging roles of MUC4 in cancer:a novel target for diagnosis and therapy [J]. Cancer Research, 2007(2):433.doi: 10.1158/0008-5472.CAN-06-3114.
    Williams SJ, Wreschner DH, Tran M. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells [J]. Journal of Biological Chemistry, 2001, (21):18327.
    Chaturvedi P, Singh AP, Moniaux N. MUC4 mucin potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with its interaction to extracellular matrix proteins [J]. Molecular Cancer Research, 2007(4):309.
    Celso A Reis, Hugo Osorio, Luisa Silva, Catarina Gomes, Leonor David. Alterations in glycosylation as biomarkers for cancer detection [J]. Journal of Clinical Pathology, 2010.322.
    Chauhan SC, Singh AP, Ruiz F. Aberrant expression of MUC4 in ovarian carcinoma:diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) [J]. Modern Pathology, 2006, (10):1386.
    Karavasilis V, Malamou-Mitsi V, Briasoulis E. Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage Ⅲ ovarian carcinoma [J]. International Journal of Gynecological Cancer, 2006, (Suppl.1):241.doi: 10.1111/j.1525-1438.2006.00316.x.
    Stav Sapoznik, Batya Cohen, Yael Tzuman, Gila Meir, Shifra Ben-Dor, Alon Harmelin. Michal Neeman Gonadotropin-Regulated Lymphangiogenesis in Ovarian Cancer Is Mediated by LEDGF-Induced Expression of VEGF-C [J]. Cancer Research, 2009.9306.
    Xiaoyun Liao, Michelle K, Y.Siu, Christy W.H.Au, Esther S.Y.Wong, Hoi Yan Chan, Philip P.C.Ip, Hextan Y.S.Ngan, Annie N.Y.Cheung. Aberrant activation of hedgehog signaling pathway in ovarian cancers:effect on prognosis, cell invasion and differentiation [J]. Carcinogenesis, 2009.131.
    • 相关文章
    • 施引文献(7)

  • 期刊类型引用(7)

    1. 马德亮，秦静，乔丽，李京烨，张洪叶. 聚乙二醇化重组人粒细胞刺激因子在预防白蛋白结合型紫杉醇联合替吉奥治疗晚期胰腺癌所致的中性粒细胞减少中的作用研究. 中国医药指南. 2023(10): 14-17 . 百度学术
    2. 孙悦，邵寿鹏，黎超. 聚乙二醇化重组人粒细胞刺激因子二级预防卵巢癌化疗后中性粒细胞减少的疗效分析. 中外医疗. 2023(10): 116-119+124 . 百度学术
    3. 刘运慧，杨秋敏，林春丽，郝蕊. 注射用黄芪多糖辅助原发性肝癌化疗的应用及安全性研究. 国际医药卫生导报. 2023(17): 2442-2445 . 百度学术
    4. 佟晶晶. 优质护理对肿瘤化疗患者护理满意度及生活质量的影响. 中国医药指南. 2022(07): 161-164 . 百度学术
    5. 曾华. 重组人粒细胞集落刺激因子针剂升白细胞近期反应研究. 吉林医学. 2021(06): 1411-1412 . 百度学术
    6. 倪玲娜，陆超，刘永，蒋敏，徐珍. 聚乙二醇化重组人粒细胞刺激因子注射液治疗恶性肿瘤患者化疗后骨髓抑制的临床疗效观察. 名医. 2020(14): 85-86 . 百度学术
    7. 张喜琴，祝守慧，刘宁，王玉，陈家帧，胡旭东. PEG-rhG-CSF对80例小细胞肺癌同步放化疗预防中性粒细胞减少的临床观察. 山东大学学报(医学版). 2020(12): 43-46+59 . 百度学术

    其他类型引用(0)

    • 资源附件(0)
计量
  • 文章访问数:  278
  • HTML全文浏览量:  24
  • PDF下载量:  16
  • 被引次数: 7
出版历程
  • 发布日期:  2010-08-15

目录

摘要
HTML全文
    参考文献(14)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    x 关闭 永久关闭